1. Home
  2. GOSS

as of 12-09-2025 4:00pm EST

$3.45
+$0.04
+1.17%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Chart Type:
Time Range:
Founded: 2015 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 726.8M IPO Year: 2019
Target Price: $8.60 AVG Volume (30 days): 2.8M
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.69 EPS Growth: N/A
52 Week Low/High: $0.71 - $3.60 Next Earning Date: 11-05-2025
Revenue: $44,051,000 Revenue Growth: -58.17%
Revenue Growth (this year): -62.48% Revenue Growth (next year): 6.41%

AI-Powered GOSS Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 77.85%
77.85%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: